Revolution Medicines (RVMD) Non-Current Deferred Tax Liability (2019 - 2026)

Revolution Medicines has reported Non-Current Deferred Tax Liability for 8 years, with the latest figure at $2.4 million in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $2.4 million in Q2 2026; TTM through Jun 2026 was $2.4 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $2.4 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability was $2.4 million for Q2 2026 at Revolution Medicines, roughly flat from $2.4 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $7.4 million in Q1 2022, with the low at $2.4 million in Q4 2024.
• Average Non-Current Deferred Tax Liability over 5 years is $4.2 million, with a median of $3.1 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability changed 0.0% in 2022, then plunged 55.82% in 2023.
• Over 5 years, Non-Current Deferred Tax Liability stood at $7.0 million in 2022, then plunged by 55.66% to $3.1 million in 2023, then decreased by 24.46% to $2.4 million in 2024, then changed by 0.0% to $2.4 million in 2025, then changed by 0.0% to $2.4 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $2.4 million (Q2 2026), $2.4 million (Q1 2026), and $2.4 million (Q4 2025), per Business Quant data.